Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics' stock experienced a 77% surge over the past year to April 8, 2026, and a 62.50% increase from April 9, 2025, to April 8, 2026, with a 52-week low of approximately $8.18-$8.20 and a high of $22.44-$22.50. The company's first-quarter fiscal 2026 results showed a revenue decline to $6.3 million and a wider net loss of $87.2 million, but the market reaction was muted due to the advancing clinical pipeline and $540.7 million in cash reserves. Clinical advancements, such as patient enrollment in the Phase 2 DAYBreak CLL-201 trial and plans to initiate the Phase 3 DAYBreak CLL-306 trial, have influenced the stock. Sanofi extended a license for STAT6, and Nurix received FDA Orphan Designation for Bexobrutideg in Waldenstrom Macroglobulinemia.

As a clinical-stage biopharmaceutical company, Nurix Therapeutics does not have commercialized products that exhibit traditional demand seasonality. The company's revenue is driven by collaboration agreements, and its financial performance is tied to research and development milestones and clinical trial progress.

Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines for cancer and inflammatory diseases, utilizing its DELigase platform with AI and E3 ligase expertise. The company's pipeline includes NX-5948 (Bexobrutideg) in Phase 2 trials for B-cell malignancies and autoimmune diseases with a planned Phase 3 trial in 2026 for CLL, NX-2127 (Zelebrudomide) in Phase 1a/1b trials for B-cell malignancies, and NX-1607, a CBL-B inhibitor. Nurix is also advancing preclinical degraders and DACs, including partnered programs with Sanofi and Gilead.

Nurix Therapeutics has a presence in the United States, with its corporate headquarters in San Francisco, California. It has expanded its office footprint to include R&D centers in Brisbane, California, and The Woodlands, Texas.

Nurix Therapeutics has a consensus rating of "Moderate Buy" from analysts, with an average rating score of 2.93 and a consensus price target of $30.46. The market's reaction to weaker Q1 2026 financial results was relatively muted, with focus remaining on the clinical pipeline and strong cash position. The news sentiment score for Nurix Therapeutics is -0.12.

Nurix Therapeutics is primarily owned by institutional shareholders, holding approximately 73.58% to 110.29% of the company's stock. Major institutional owners include BlackRock, Inc., Redmile Group, LLC, Deep Track Capital, LP, Vanguard Group Inc, General Atlantic Llc, Morgan Stanley, Vestal Point Capital, LP, Baker Bros. Advisors Lp, Fmr Llc, and State Street Corp. Insider ownership ranges from approximately 0.20% to 8.26%, while retail investors hold around 0.00% to 21.06%. Third Rock Ventures III LP is the largest individual shareholder, owning 3.51 million shares, representing 3.41% of the company.